Kai Zhang*, Huajun Chen†, Ye Wang‡, Lin Yang§, Chengzhi Zhou¶, Weiqiang Yin#, Guangsuo Wang§,
Xinru Mao**, Jianxing Xiang**, Bing Li**, Tengfei Zhang**, Shihong Fei*
Oncology Research, Vol.27, No.5, pp. 575-582, 2019, DOI:10.3727/096504018X15344979253618
Abstract RET rearrangement has been proven as an oncogenic driver in patients with lung cancer. However, the prevalence, clinical characteristics, molecular features, and therapeutic options in RET-rearranged patients remain
unclear, especially in Chinese lung cancer patients. We retrospectively collected 6,125 Chinese lung cancer
patients who have been profiled using next-generation sequencing (NGS). The clinical demographics and
molecular features of RET rearrangement-positive patients were analyzed. RET rearrangements were identified in 84 patients with a proportion of 1.4% in our cohort. The median age at diagnosis was 58 years, and it
mainly occurred in females with adenocarcinoma histology. KIF5B-RET was the… More >
Login
Register
